Cold-Pressed Evening Primrose Oil (Oenothera biennis)

Cold-pressed evening primrose oil is derived from Oenothera biennis seeds and is rich in gamma-linolenic acid (GLA, 8.9–9.7%) and tocopherols (~770 mg/kg). GLA serves as a direct precursor to dihomo-gamma-linolenic acid (DGLA), which competes with arachidonic acid in eicosanoid synthesis to modulate inflammatory signaling.

Origin & History

Cold-pressed evening primrose oil is a fixed oil extracted mechanically from the seeds of Oenothera biennis (evening primrose plant) without heat or chemicals to preserve nutrients. The oil consists primarily of triacylglycerols containing 70-74% linoleic acid and 8-10% γ-linolenic acid, with minor components including palmitic, oleic, and stearic acids.

Historical & Cultural Context

The research dossier provides no information on historical context, traditional medicine systems, indications, or duration of use for evening primrose oil.

Health Benefits

• No specific health benefits can be confirmed from clinical trials as the research dossier contains no human clinical studies, RCTs, or meta-analyses
• Contains γ-linolenic acid (8.9-9.7%), a precursor to anti-inflammatory compounds, though no clinical evidence provided
• Rich in tocopherols (770 ppm, mainly gamma-tocopherol) with antioxidant properties, but lacks clinical validation
• Contains phytosterols including beta-sitosterol (~9000 ppm), though no clinical outcomes documented
• May influence arachidonic acid pathways via phospholipase A2 and C mechanisms, but this is theoretical without clinical support

How It Works

GLA from evening primrose oil is elongated by delta-6-desaturase to dihomo-gamma-linolenic acid (DGLA), which is converted by COX enzymes into 1-series prostaglandins (e.g., PGE1) that exert anti-inflammatory and vasodilatory effects. DGLA also competitively inhibits the conversion of arachidonic acid to pro-inflammatory 2-series prostaglandins and 4-series leukotrienes via COX-2 and 5-LOX pathways. Additionally, tocopherols in the oil act as lipid-soluble antioxidants, quenching peroxyl radicals and protecting polyunsaturated fatty acids from lipid peroxidation within cell membranes.

Scientific Research

The research dossier explicitly states that search results provide no specific human clinical trials, RCTs, or meta-analyses for cold-pressed evening primrose oil. No PubMed PMIDs or details on study designs, sample sizes, or clinical outcomes are available in the provided sources.

Clinical Summary

The current research dossier for cold-pressed evening primrose oil contains no human clinical trials, randomized controlled trials, or meta-analyses specific to this cold-pressed form, limiting the ability to confirm efficacy for any health outcome. Conventional (non-cold-pressed) evening primrose oil has been studied in small RCTs for conditions such as atopic dermatitis, premenstrual syndrome, and mastalgia, with mixed and generally modest results. A 2013 Cochrane review on evening primrose oil for eczema found insufficient evidence to support its use, citing poor trial quality and small sample sizes. Due to the absence of dossier-specific clinical data, any health claims for this ingredient remain mechanistically plausible but clinically unverified.

Nutritional Profile

Cold-pressed evening primrose oil is composed almost entirely of lipids (~99-99.5% total fat), with no meaningful protein, carbohydrate, or fiber content. Fatty acid composition (per 100g oil): linoleic acid (omega-6, LA) ~65-80%, γ-linolenic acid (GLA, omega-6) ~8-10% (typically 8.9-9.7% per dossier data), oleic acid (omega-9) ~6-10%, palmitic acid (saturated) ~5-7%, stearic acid (saturated) ~1-3%, α-linolenic acid (omega-3) trace amounts <0.5%. GLA is the principal bioactive fatty acid, serving as a direct precursor to dihomo-γ-linolenic acid (DGLA) and subsequently to prostaglandin E1 (PGE1), bypassing the rate-limiting delta-6-desaturase enzyme step. Micronutrient content: tocopherols ~770 ppm total (predominantly gamma-tocopherol ~600-650 ppm, with minor alpha-, beta-, and delta-tocopherol fractions), contributing antioxidant activity and oxidative stability to the oil. Phytosterols present at approximately 300-500 mg/100g, primarily beta-sitosterol. Polyphenols present in trace quantities. Energy density approximately 884 kcal/100g (9 kcal/g fat). Bioavailability notes: GLA from evening primrose oil is well-absorbed via lymphatic chylomicron transport; bioavailability is enhanced when consumed with meals containing other fats. Cold-pressing preserves tocopherol and GLA integrity versus solvent extraction or high-heat processing. Oil is highly susceptible to oxidative rancidity due to high polyunsaturated fat content; nitrogen-flushed, dark glass packaging is required to maintain potency.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are reported in the available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other gamma-linolenic acid sources, omega-3 fatty acids, vitamin E, antioxidant compounds, anti-inflammatory herbs

Safety & Interactions

Evening primrose oil is generally well tolerated at typical doses of 2–8 g/day, with the most common adverse effects being mild gastrointestinal symptoms such as nausea, loose stools, and bloating. It may lower the seizure threshold and is contraindicated in individuals with epilepsy or those taking phenothiazine antipsychotics such as chlorpromazine. Due to its prostaglandin-modulating effects, caution is warranted with anticoagulants like warfarin, as GLA-derived PGE1 may inhibit platelet aggregation and increase bleeding risk. Safety data in pregnancy is insufficient; use during pregnancy or lactation should be avoided unless supervised by a healthcare provider.